Critically analyze the concept of evergreening in the context of Section 3(d) of the Patents Act. What challenges does it pose for innovation and public health in India?

Question

PocketIAS · Accepted Answer

Introduction

Evergreening refers to strategies used by pharmaceutical companies to extend the monopoly of a patented drug through minor modifications without significant therapeutic improvement. In India, Section 3(d) of the Patents Act, 1970 acts as a safeguard by preventing patents for new forms of known substances unless they demonstrate enhanced therapeutic efficacy.

Concept of Evergreening and Section 3(d)

Evergreening Practices: Pharmaceutical firms introduce incremental changes such as new salts, polymorphs, formulations, or dosage forms to extend patent life beyond the original term.
Purpose of Section 3(d): It prevents trivial modifications from receiving patent protection and ensures that only genuine innovations with improved efficacy are granted patents.
Judicial Interpretation: The Novartis v. Union of India (2013) case clarified that mere improvements in physical properties or stability are insufficient; significant therapeutic efficacy must be proven.

Challenges for Innovation

Reduced Incentives for Incremental Innovation: Critics argue that strict interpretation of Section 3(d) may discourage pharmaceutical companies from investing in improvements to existing drugs.
Uncertainty in Patentability: Determining “enhanced efficacy” can be complex, creating ambiguity for patent applicants and regulators.
Global Industry Concerns: Multinational companies claim it may reduce foreign investment in pharmaceutical research within India.

Implications for Public Health

Improved Access to Medicines: By restricting evergreening, Section 3(d) facilitates earlier entry of generic medicines, making drugs more affordable.
Strengthening India’s Generic Industry: It supports India’s role as the “pharmacy of the developing world,” ensuring supply of low-cost medicines globally.
Balancing TRIPS Compliance: India maintains compliance with international intellectual property norms while prioritizing public health interests.

Conclusion

Section 3(d) represents a crucial policy tool that balances innovation incentives with public health needs. While concerns regarding incremental innovation remain, its role in preventing patent abuse and ensuring affordable access to medicines is vital for India and other developing countries.

✍️ Practice Mode

Write. Evaluate. Improve. Repeat.

The model answer is ready.

Comments (0)